Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Advanced Parkinson's Disease Clinical Trial

Official title:

Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00660673
• Other study ID #: S187.3.005
• Secondary ID: 2008-001329-33
• Status: Completed
• Phase: Phase 3
• Start date: November 13, 2009
• Est. completion date: November 30, 2021

Study information

• Verified date: November 2022
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment (Study S187.3.003 [NCT00360568] or Study S187.3.004 [NCT00335153]).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 262
• Est. completion date: November 30, 2021
• Est. primary completion date: November 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 99 Years

Eligibility

Inclusion Criteria:

• The participant should have completed participation in Study S187.3.003 or S187.3.004; and, in the opinion of the Principal Investigator, would benefit from long-term treatment with LCIG.
• For Canada, participants will be allowed to participate in the S187.3.005 study with a minimum of 6 months of exposure to LCIG in the S187.3.004 study.
• The participant must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study related procedures. If the participant does not have the capacity to provide informed consent, full informed consent must be obtained from the participant's legally authorized representative. Consenting will be performed according to local regulations.

Exclusion Criteria:

• Medical, laboratory, psychiatric, or surgical issues deemed by the investigator to be clinically significant and which could interfere with the participant's participation in the study.

Related Conditions & MeSH terms

• Advanced Parkinson's Disease
• Parkinson Disease

Intervention

Drug:
• Levodopa-Carbidopa Intestinal Gel (LCIG)
LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.

Device:
• CADD-Legacy® 1400 ambulatory infusion pump
Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
• Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
All participants previously had a PEG-J placed in one of the prior LCIG studies.

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital /ID# 50083	Adelaide	South Australia
Australia	Austin Hospital /ID# 50082	Heidelberg	Victoria
Australia	Westmead Hospital /ID# 50081	Westmead	New South Wales
Canada	University of Alberta /ID# 78476	Edmonton	Alberta
Canada	CHUM - Notre-Dame Hospital /ID# 74513	Montréal	Quebec
Canada	Toronto Western Hospital /ID# 75913	Toronto	Ontario
Czechia	Fakultni Nemocnice u Svate Anny /ID# 50085	Brno
Czechia	Fakultni nemocnice Hradec Kralove /ID# 50088	Hradec Králové
Czechia	Pardubicka krajska nemocnice, a.s.	Pardubice
Czechia	Fakultni Nemocnice v Motole /ID# 50084	Praha
Czechia	Vseobecna fakultni nemocnice v Praze /ID# 50086	Praha
Israel	Tel Aviv Sourasky Medical Center /ID# 50089	Tel-Aviv
New Zealand	Auckland City Hospital /ID# 50093	Auckland
New Zealand	New Zealand Brain Research Institute/ID# 50090	Christchurch
New Zealand	Waikato Hospital /ID# 50091	Hamilton	Waikato
New Zealand	Wellington Hospital /ID# 50092	Wellington
Poland	Miejskie Centrum Medyczne im. dr. Karola Jonschera w Lodzi /ID# 50096	Lódz	Lodzkie
Poland	NZOZ Centrum Medyczne HCP /ID# 50094	Poznan	Wielkopolskie
Portugal	Hospitais da Universidade de Coimbra /ID# 50098	Coimbra
Portugal	Hospital de Santa Maria /ID# 50099	Lisboa
Portugal	Centro Hospitalar Universitario de Sao Joao, EPE /ID# 50101	Porto
Russian Federation	Scientific Research Medical Complex Your Health /ID# 50104	Kazan
Russian Federation	Institution of the Russian Academy of Medical Sciences Scientific Centre of Neurology /ID# 50102	Moscow
Russian Federation	City Clinical Hospital #40 /ID# 50106	Saint Petersburg
Russian Federation	I.P. Pavlov First St. Petersburg State Medical University /ID# 50107	Saint Petersburg
Russian Federation	Military Medical Academy n.a. Kirov /ID# 50103	Saint Petersburg
Thailand	King Chulalongkorn Mem Hosp /ID# 50108	Bangkok
Thailand	Siriraj Hospital /ID# 50109	Bangkok
United Kingdom	The Walton Centre NHS Foundation /ID# 50003	Liverpool
United Kingdom	National Hospital for Neurology & Neurosurgery	London
United States	Georgia Regents University /ID# 49938	Augusta	Georgia
United States	Johns Hopkins University /ID# 49937	Baltimore	Maryland
United States	Univ Maryland School Medicine /ID# 49934	Baltimore	Maryland
United States	University of Alabama at Birmingham /ID# 49941	Birmingham	Alabama
United States	Bradenton Research Center, Inc /ID# 49929	Bradenton	Florida
United States	University of Vermont Medical Center /ID# 49912	Burlington	Vermont
United States	Northwestern University Feinberg School of Medicine /ID# 49944	Chicago	Illinois
United States	Rush University Medical Center /ID# 49930	Chicago	Illinois
United States	University of Cincinnati /ID# 49914	Cincinnati	Ohio
United States	Cleveland Clinic Main Campus /ID# 76173	Cleveland	Ohio
United States	The Research Center of Southern California /ID# 49928	Encinitas	California
United States	Colorado Neurological Institute /ID# 49927	Englewood	Colorado
United States	Neurologic Consultants, PA /ID# 49918	Fort Lauderdale	Florida
United States	The Parkinson's & Movement Disorder Institute - Fountain Valley /ID# 49915	Fountain Valley	California
United States	University of Florida - Archer /ID# 49935	Gainesville	Florida
United States	University of Florida /ID# 49922	Jacksonville	Florida
United States	King County Public Hospital /ID# 49917	Kirkland	Washington
United States	University of Kentucky Chandler Medical Center /ID# 49940	Lexington	Kentucky
United States	Universtiy of Southern California /ID# 49913	Los Angeles	California
United States	North Shore University Hospital /ID# 49932	Manhasset	New York
United States	Froedtert Memorial Lutheran Hospital /ID# 49924	Milwaukee	Wisconsin
United States	Columbia Univ Medical Center /ID# 49943	New York	New York
United States	The Mount Sinai Hospital /ID# 49942	New York	New York
United States	University of Nebraska Medical Center /ID# 49911	Omaha	Nebraska
United States	Charlotte Neurological Service /ID# 49916	Port Charlotte	Florida
United States	Raleigh Neurology Associates /ID# 49923	Raleigh	North Carolina
United States	Washington University-School of Medicine /ID# 49933	Saint Louis	Missouri
United States	Louisiana State Univ HSC /ID# 49945	Shreveport	Louisiana
United States	University of South Florida /ID# 49919	Tampa	Florida
United States	Georgetown University Hospital /ID# 49931	Washington	District of Columbia
United States	Wake Forest Univ HS /ID# 49939	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
AbbVie	IQVIA, formerly Quintiles

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Czechia,  Israel,  New Zealand,  Poland,  Portugal,  Russian Federation,  Thailand,  United Kingdom, 

References & Publications (1)

Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, Espay AJ. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in adva — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment-emergent Adverse Events	Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) which started on or after the date of the first LCIG Infusion in this study and within 30 days of the date of the last PEG-J exposure.; At least possibly drug-related is defined as TEAEs assessed as having a "Possible" or "Probable" or missing relationship to study drug.; Serious AEs included any untoward medical occurrence that: Resulted in death; Was life-threatening; Required inpatient hospitalization or prolongation of an existing hospitalization; Resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; The severity of all AEs was characterized as mild, moderate or severe according to the following definitions: Mild: usually transient and do not interfere with daily activities.; Moderate: low level of inconvenience or concern to the subject, may interfere with daily activities.; Severe: events interrupt the subject's usual daily activity.	From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).
Secondary	Number of Participants With Device Complications	Device complications include complications with the pump, intestinal tube, PEG-J or stoma.	From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days.
Secondary	Number of Participants With Sleep Attacks	Participants were asked whether they experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. If yes, participants were asked if they suffered any "bad" outcome or problem from the falling asleep event.	Baseline (final assessment period of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Secondary	Number of Participants With Intense Impulsive Behavior	To monitor for the development of intense impulsive behavior the Minnesota Impulsive Disorder Interview (MIDI) was administered. The MIDI is a semi-structured clinical interview assessing pathological gambling, trichotillomania, kleptomania, pyromania, intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.	Baseline (final assessment of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Secondary	Number of Participants Who Developed Melanoma	A comprehensive assessment for the presence of melanoma was performed at least once a year by a dermatologist.	Once per year during the study; median duration of treatment was 1178 days.
Secondary	Number of Participants With Treatment-emergent Adverse Events of Special Interest (TE AESI)	Adverse events of special interest (AESIs) were identified using standardized Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQ) or company MedDRA queries (CMQs). The AESI in the following categories were identified on the basis of review of the clinical program and postmarketing observations where the treatment system is commercially available.; Procedure and device associated events; Polyneuropathy, included preferred terms in either the peripheral neuropathy or GuillainBarre syndrome standardized MedDRA query (narrow search), such as polyneuropathy, decreased vibratory sense, peripheral neuropathy, peripheral sensory neuropathy, neuralgia, demyelinating polyneuropathy, and sensory disturbance; Weight loss; Cardiovascular fatalities; Respiratory tract aspiration including aspiration pneumonia/pneumonitis.	From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).
Secondary	Number of Participants With Any Suicidal Ideation or Behavior	The Columbia-Suicide Severity Rating Scale (C-SSRS) was implemented with Protocol Amendment 3 (20 March 2012) in order to assess suicidal behavior and ideation.; Suicidal ideation includes the wish to be dead, nonspecific active suicidal thoughts, active ideation without intent to act, active ideation with some intent to act, and active ideation with specific plan or intent. Suicidal behavior includes actual attempts, interrupted attempts, aborted attempts, completed suicide, and preparatory acts or behaviors.; The number of participants with affirmative responses on the C-SSRS at any time during the treatment period is reported.	Every 6 months (beginning with implementation of Protocol Amendment 3) until final visit; median duration of treatment was 1178 days.
Secondary	Number of Participants With Potentially Clinically Significant Vital Sign Values	A vital sign value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.	Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Secondary	Number of Participants With Potentially Clinically Significant Hematology Laboratory Values	A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.	Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Secondary	Number of Participants With Potentially Clinically Significant Chemistry Laboratory Values	A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding baseline value.; ULN = upper limit of normal	Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Secondary	Number of Participants With Vitamin Levels Outside of the Normal Range	Special tests for vitamin deficiencies (folic acid, vitamin B6, vitamin B12, methylmalonic acid [MMA], and homocysteine) were implemented with Protocol Amendment 2 (27 July 2011). The number of participants with vitamin levels outside of the normal range at any time post-baseline is reported for each vitamin tested.	Every 6 months (beginning with implementation of Protocol Amendment 2) until final visit; median duration of treatment was 1178 days.
Secondary	Number of Participants Receiving Concomitant Anti-Parkinson's Disease Medications by Treatment Year	Participants could use oral levodopa-carbidopa for scheduled or supplemental bedtime/overnight doses after the pump was disconnected for the night, or as rescue medication in case of acute deterioration caused by failure of the LCIG system such as tubes and/or the pump or the onset of an acute illness.; The initiation of additional concomitant PD medication was allowed at the discretion of the Investigator if medically indicated.	Year 1, Year 2, Year 3, Year 4, Year 5, Year 6, Year 7, Year 8, Year 9, Year 10, > Year 10 (maximum time on treatment was approximately 11.5 years).
Secondary	Change in Average Daily "Off" Time Based on the Parkinson's Disease Symptom Diary at End of Treatment	The PD symptom diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia.; "Off" time was defined as time when medication had worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness.; PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit.; A negative change for "off" time indicates improvement. The PD diary assessment was implemented with Protocol amendment 4 (December 2013) for participants at United States (US) sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary	Change in Average Daily "On" Time Without Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment	The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia.; "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Non-troublesome dyskinesia does not interfere with function or cause meaningful discomfort.; "On" time without troublesome dyskinesia is the sum of "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement.; The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary	Change in Average Daily "On" Time With Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment	The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia.; "On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Troublesome dyskinesia interferes with function or causes meaningful discomfort.; PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement.; The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary	Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias).; The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.; The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary	Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias).; The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.; The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary	Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias).; UPDRS Part III consists of 14 questions. Questions 20 - 26 are multi-part questions in that they are evaluated separately for multiple body parts. Counting each of these assessments leads to a total of 27 answers for Part III. The UPDRS Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-Point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.; The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary	Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including dyskinesias).; The UPDRS total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I - III of the scale. The total score ranges from 0 - 176 with 176 representing the worst (total) disability, and 0 no disability. A negative change from Baseline indicates improvement.; The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary	Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias).; The UPDRS Part IV Score is the sum of all answers to the 11 questions that comprise Part IV, 4 of which are measured on a 5-point scale (0 - 4) and 7 which are measured on a 2-point scale (0 - 1). The Part IV score ranges from 0 - 23 with higher scores associated with more disability. A negative change from Baseline indicates improvement.; The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary	Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Dyskinesia Score at End of Treatment	The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections: I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias); and; The UPDRS Part IV dyskinesia Score is the sum of Questions 32 (What proportion of the waking day are dyskinesias present?), 33 (How disabling are the dyskinesias? ), and 34 (How painful are the dyskinesias?) on UPDRS Part IV, each of which are measured on a 5-point scale (0-4). The Part IV dyskinesia score ranges from 0 - 12 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.; The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary	Change in Parkinson's Disease Questionnaire (PDQ-39) Scores at End of Treatment	The PDQ-39 is a self-administered questionnaire that comprises 39 items addressing the following eight domains of health that patients consider to be adversely affected by the disease: Mobility (e.g., fear of falling when walking) - 10 questions; Activities of daily living (e.g., difficulty cutting food) - 6 questions; Emotional well-being (e.g., feelings of isolation) - 6 questions; Stigma (e.g., social embarrassment) - 4 questions; Social support - 3 questions; Cognition - 4 questions; Communication - 3 questions; Bodily discomfort - 3 questions; Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness. The PDQ-39 summary index (range 0-100) includes responses to all 39 items. A negative change indicates improvement.	Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.

External Links

•   Related Info